A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Trial Profile

A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Amyloid light-chain amyloidosis; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Solid tumours; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 30 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top